| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 661,590 | 682,687 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 159 | 97 |
| Net increase in cash, cash equivalents, and restricted cash | 688,954 | 654,659 |
| Cash and cash equivalents at beginning of period | 68,028 | - |
| Cash and cash equivalents at end of period | 756,982 | - |
Caris Life Sciences, Inc. (CAI)
Caris Life Sciences, Inc. (CAI)